| Size | Price | |
|---|---|---|
| Other Sizes |
| ln Vitro |
The degree to which sulfate reduction is inhibited is correlated with the inhibition of bacterial growth caused by salicylamide therapy [1].
|
|---|---|
| ln Vivo |
The administration of salicylamide decreases the amounts of radioactive sulfate in the placenta and maternal serum, and hinders the binding of radioactive sulfate to skeletal GAGs in the fetus. The calcium content of embryonic limb bones decreases when salicylamide is administered; however, maternal serum calcium levels are not significantly affected [2]. In a dose-dependent way, salicylamide administration lowers the absorption of radioactive sulfate from mother serum and the liver, fetus, and placenta. Salicylamide-induced changes in fetal and placental radiosulfate uptake over time were also noteworthy, and they were unrelated to the amounts of radiosulfate in the mother's serum [3].
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
After oral administration, the drug is absorbed and excreted very rapidly, thus preventing the attainment of high plasma concentrations. It diffuses rapidly into various body tissues and larger volumes of body fluids… Animal studies have shown that… it diffuses rapidly into the brain. In rabbits, the rate of transport of free drug across the basement membrane is limited by blood flow, while the transport of glucuronide is limited by epithelial cell transport steps, not by the rate of synthesis. …When salicylamide doses exceed approximately 1 gram… significant levels of unconverted drug appear in plasma. Human bioavailability studies… indicate that oral sodium salicylamide solution is absorbed faster than oral salicylamide tablets. Sodium salts have an earlier onset of action than salicylamide, and the sedative effect of both formulations increases with increasing dose. For more complete data on the absorption, distribution, and excretion of salicylamides (9 in total), please visit the HSDB records page. Metabolism/Metabolites After oral administration of salicylamide, it is bound via the intestinal mucosa… No glucuronide conjugates were detected in the urine of cats after administration of salicylamide.Compared to rabbits, cats produced increased levels of sulfate conjugates, with significantly higher levels of 2,3-dihydroxybenzamide. In humans, salicylamide produces salicylamide-2-β-D-glucuronide and salicylamide-2-sulfate. /Excerpt from a table/ After administration of 5 mg/kg salicylamide (dissolved in 5 mg/kg Tylenol suspension) to children, 78% of the dose is excreted as salicylamide sulfate; in adults, it is 36%. In adults, glucuronide is the major metabolite. Children with glucuronide deficiency have an increased rate of sulfate formation. For more complete data on the metabolism/metabolites of salicylamide (10 metabolites in total), please visit the HSDB record page. |
| References |
|
| Additional Infomation |
2-Hydroxybenzamide is an odorless, white or slightly pink crystal. It has a bitter taste and a warming sensation upon ingestion. A saturated aqueous solution has a pH of approximately 5 at 82°F (28°C). Sublimation begins at the melting point. (NTP, 1992)
Salicylic acid amide is the simplest member of the salicylamide class of compounds derived from salicylic acid. It is a non-narcotic analgesic and antirheumatic drug. It belongs to the salicylamide and phenolic compounds. Salicylic acid amide is the common name for o-hydroxybenzamide or salicylamide. Salicylamide is an over-the-counter drug with analgesic and antipyretic effects. Its medicinal value is similar to that of aspirin. Salicylamide is often used in combination with aspirin and caffeine in over-the-counter analgesics. Salicylic acid amide has been reported in Streptomyces spectabilis and Streptomyces rimosus, and relevant data are available. |
| Molecular Formula |
C7H7NO2
|
|---|---|
| Molecular Weight |
137.1360
|
| Exact Mass |
137.047
|
| CAS # |
65-45-2
|
| Related CAS # |
36205-82-0 (mono-hydrochloride salt)
|
| PubChem CID |
5147
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
279.7±42.0 °C at 760 mmHg
|
| Melting Point |
140-144 °C(lit.)
|
| Flash Point |
122.9±27.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.579
|
| LogP |
1.11
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SKZKKFZAGNVIMN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)
|
| Chemical Name |
2-hydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~729.18 mM)
H2O : ~0.1 mg/mL (~0.73 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2918 mL | 36.4591 mL | 72.9182 mL | |
| 5 mM | 1.4584 mL | 7.2918 mL | 14.5836 mL | |
| 10 mM | 0.7292 mL | 3.6459 mL | 7.2918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
